UPDATE: Leerink Swann Raises PT on The Medicines Company Following Analyst Meeting
October 10, 2013 at 10:56 AM EDT
In a report published Thursday, Leerink Swann analyst Joseph P. Schwartz reiterated an Outperform rating on The Medicines Company (NASDAQ: MDCO ), and raised the price target from $40.00 to $42.00. In the report, Leerink Swann noted, “At today's analyst meeting, MDCO reviewed the status of its ongoing Angiomax patent
